Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis

Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis

IntroductionChemotherapy (CT) is commonly used as an adjuvant treatment for women with early breast cancer (BC). However, not all patients benefit from CT, while all are exposed to its short- and long-term toxicity. The Oncotype DX® test assesses cancer-related gene expression to estimate the risk o...

Full description

Bibliographic Details
Main Authors: Elsa Curtit, Martine Marie Bellanger, Virginie Nerich, Delphine Hequet, Jean-Sebastien Frenel, Olivier Cristeau, Roman Rouzier
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
genomic signatures
adjuvant chemotherapy
cost-effectiveness analysis
early breast cancer
decision impact
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1191943/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1191943/full

Similar Items